Document is current
Any future updates will be listed below
-
Authors
Mathur, Sameer
Corbridge, Thomas
Packnett, Elizabeth
Jariwala-Parikh, Krutika
Deb, Arijita
-
Funding
Funding for this research was provided by:
GSK (GSK ID: 214470)
- License Information
-
More Information
Article History
Received: 5 July 2023
Accepted: 6 October 2024
First Online: 24 October 2024
Declarations
:
: This article is based on information obtained from utilizing the Merative Explorys<sup>®</sup> Universe electronic health records database. This study used only de-identified patient records and did not involve the collection, use or transmittal of individually identifiable data thus, Institutional Review Board (IRB) approval was not necessary.
: Not applicable.
: <b>SM</b> is a speaker for GSK, AstraZeneca and Regeneron, and has acted as a consultant for AstraZeneca. <b>TC</b> and <b>AD</b> are employees of GSK and own stocks/shares. <b>EP</b> is an employee of Merative, which received payment from GSK to conduct this study. <b>KJ-P</b> is a former employee of Merative, which received payment from GSK to conduct this study.
